Application of nicotinamide adenine dinucleotide in preparation of antiplatelet drugs

By using nicotinamide adenine dinucleotide (NAD+) to inhibit platelet aggregation and release, the existing antiplatelet drugs have been solved in the slow onset of effect, high bleeding risk and drug resistance, and effective prevention of arterial thrombotic diseases has been achieved. and treatment, new drug regimens are provided.

CN119055668APending Publication Date: 2024-12-03ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411173226.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-26
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing antiplatelet drugs such as P2Y12 receptor antagonists have slow onset, slow platelet function recovery after discontinuation, large individual differences, high risk of bleeding, and have side effects such as drug resistance and gastrointestinal injury, which cannot fully meet the clinical conditions. The prevention and treatment needs of cardiovascular and cerebrovascular thrombotic diseases.

Method used

Niacinamide adenine dinucleotide (NAD+) is used as an antiplatelet drug to slow down thrombosis by inhibiting the aggregation and release of platelets, as a single component or in combination with P2Y12 receptor antagonist, for the prevention and treatment of arterial thrombosis disease.

Benefits of technology

NAD+ significantly inhibits agonist-induced platelet aggregation and thrombosis, slows down the formation process of arterial thrombosis without increasing the risk of bleeding, and provides a new antiplatelet drug regimen with clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005009950910000021
    Figure BDA0005009950910000021
  • Figure HDA0005009950920000011
    Figure HDA0005009950920000011
  • Figure HDA0005009950920000012
    Figure HDA0005009950920000012
Patent Text Reader

Abstract

The invention relates to the field of biological medicines, and discloses application of nicotinamide adenine dinucleotide in preparation of an anti-platelet medicine, and discloses the anti-platelet medicine which contains a therapeutically effective amount of nicotinamide adenine dinucleotide as a unique active ingredient, or the medicine is a medicine composition, or the medicine composition is a medicine composition or an anti-platelet medicine composition or an anti-platelet medicine composition or an anti-platelet medicine composition or an anti-platelet medicine composition or an anti-platelet medicine composition or an anti-platelet medicine composition. In addition to a therapeutically effective amount of nicotinamide adenine dinucleotide as an active ingredient, the pharmaceutical composition also contains other anti-platelet pharmaceutical ingredients. The medicine can be used for preventing or treating arterial thrombotic diseases such as coronary heart disease, myocardial infarction or cerebral apoplexy, and has clinical application and development prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedicine, and more specifically, to the use of nicotinamide adenine dinucleotide in the preparation of antiplatelet drugs. Background Art

[0002] Cardiovascular and cerebrovascular diseases are the number one killer of human health, among which arterial thrombotic diseases such as myocardial infarction and stroke are the most dangerous and fatal. Platelet activation is the key link in arterial thrombosis, and antiplatelet therapy is also an important means of preventing and treating arterial thrombotic diseases. Currently, the most widely used P2Y12 receptor antagonists in clinical practice, such as clopidogrel and ticagrelor, have certain limitations, including slow onset, slow recovery of platelet function after discontinuation, and individual differences in action. However, although ticagrelor has a strong antiplatelet effect, it also has a greater risk of bleeding. Therefore, antiplatelet drugs targeting P2Y12 cannot fully meet clinical needs. Although when used in combination with drugs such as aspirin, there are still problems such as damage to the gastrointestinal mucosa, drug resistance, and increased bleeding side effects.

[0003] In summary, the development of an antiplatelet drug that is effective in anti-thrombosis and relatively safe is very important for the prevention and treatment of cardiovascular and cerebrovascular thrombotic diseases. At present, it is still necessary to continue exploring new antiplatelet targets to meet actual clinical needs. Summary of the invention

[0004] Reactive oxygen species (ROS) play a key role in regulating platelet function. Platelets are both the source and target of ROS. During platelet activation, ROS are generated to further amplify the platelet activation signal, leading to complete platelet activation and thrombus formation.

[0005] The mitochondrial respiratory chain is an important source of ROS production. Nicotinamide adenine dinucleotide (NAD+), also known as coenzyme I (CoⅠ), is a coenzyme for many dehydrogenases in the body and is an important link between the substrate and the respiratory chain. Previous studies have shown that NAD+ can inhibit the production of ROS in a variety of cells. Supplementing NAD+ can delay aging, improve heart failure and other therapeutic effects. However, the role of NAD+ in platelet activation and thrombosis has not been studied yet.

[0006] The purpose of the invention of this application is to study the role of NAD+ in platelet activation and thrombosis.

[0007] In a first aspect, the present application provides the use of NAD+ in the preparation of antiplatelet drugs.

[0008] Nicotinamide adenine dinucleotide, English name: NAD+, has the chemical structure shown in the following formula (1):

[0009]

[0010] Furthermore, the antiplatelet agent refers to the inhibition of platelet aggregation and thrombosis.

[0011] Furthermore, the antiplatelet drug is a thrombosis prevention or anti-thrombotic drug.

[0012] Furthermore, the antiplatelet drug is a drug for preventing or treating arterial thrombotic diseases.

[0013] Furthermore, the arterial thrombotic disease is coronary heart disease, myocardial infarction or cerebral stroke.

[0014] In a second aspect, the present application provides an antiplatelet drug.

[0015] The drug contains a therapeutically effective amount of nicotinamide adenine dinucleotide as the only active ingredient.

[0016] Alternatively, the drug is a pharmaceutical composition which, in addition to a therapeutically effective amount of nicotinamide adenine dinucleotide as an active ingredient, also contains other antiplatelet drug ingredients.

[0017] Furthermore, the other antiplatelet drug ingredients are selected from P2Y12 receptor antagonists, such as clopidogrel and ticagrelor.

[0018] Furthermore, the drug may further comprise one or more pharmaceutically acceptable carriers.

[0019] Furthermore, the dosage form of the drug is an oral preparation or an injection.

[0020] Furthermore, the oral preparation is selected from the group consisting of: tablets, capsules (including but not limited to dispersible capsules and gelatin capsules), granules, powders, solutions, and syrups.

[0021] Furthermore, in the oral preparation, the pharmaceutically acceptable carrier includes one or more of the following groups: fillers or extenders, binders, wetting agents, disintegrants, absorbents, lubricants, buffers, complexing agents, and colorants.

[0022] Furthermore, when the dosage form of the drug is an injection, it is suitable for intravenous injection or intravenous drip.

[0023] In summary, this application has the following beneficial effects:

[0024] The present invention discovered a new use of NAD+ in the antiplatelet field. The results of in vitro experiments on human platelets showed that NAD+ had a strong inhibitory effect on agonist-induced platelet aggregation and release; the results of spreading and thrombus retraction experiments showed that NAD+ also had a strong inhibitory effect on stable thrombus formation, suggesting that it may be used as an antiplatelet drug to prevent or treat arterial thrombotic diseases such as coronary heart disease, myocardial infarction or stroke without increasing the risk of bleeding, and has prospects for clinical application development. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 The effect of NAD+ on human platelet aggregation induced by agonist collagen was shown. Figure 1 -A is a representative graph, Figure 1 -B is the statistical curve.

[0026] Figure 2 The results of the experiment on the effect of NAD+ on arterial thrombosis in c57 mice are shown. Figure 2 -A is a representative graph, Figure 2 -B is the statistical curve.

[0027] Figure 3 The results of an experiment evaluating the effect of NAD+ on tail bleeding in c57 mice are shown. DETAILED DESCRIPTION

[0028] The technical scheme and effects of the present application are further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the invention, rather than to limit the invention.

[0029] The inventors have discovered a new antiplatelet drug, NAD+, which is expected to solve the current dilemma of antiplatelet therapy. With its antiplatelet effect, NAD+ has the potential to be used to prevent and treat arterial thrombotic diseases.

[0030] Our research group investigated the effect of NAD+ on the aggregation and release of human platelets induced by classical agonists. The results showed that NAD+ has an inhibitory effect on both the aggregation and release of human platelets induced by collagen.

[0031] The results of the study on the effect of NAD+ on arterial thrombosis in mice showed that NAD+ treatment significantly slowed down the formation process of arterial thrombosis in mice.

[0032] The results of the study on the effect of NAD+ on tail-docking bleeding in mice showed that NAD+ treatment did not affect the tail-docking bleeding time of mice.

[0033] Both in vitro platelet function experiments and in vivo thrombosis models have confirmed that NAD+ has a strong antiplatelet effect without increasing the risk of bleeding. The experimental results provide strong evidence of NAD+'s antiplatelet effect from multiple dimensions and its safety as a drug. The drug of the present invention can be used as an antiplatelet drug for the prevention and treatment of arterial thrombotic diseases such as coronary heart disease and stroke.

[0034] As an application mode of antiplatelet drugs, NAD+ is used as an active ingredient to prepare antiplatelet drugs. In the specific implementation part, in order to describe the role in the drug or pharmaceutical composition, the active ingredient NAD+ can be referred to as an "active compound".

[0035] The drug can be a single component drug containing a therapeutically effective amount of NAD+, or a pharmaceutical composition further containing other components such as a pharmaceutically acceptable carrier.

[0036] NAD+ can be used as the only active ingredient in the drug, or it can be used in combination with other antiplatelet drug ingredients such as P2Y12 receptor antagonists. For example, NAD+ can be used in combination with other antiplatelet drug ingredients such as clopidogrel or ticagrelor as two active compounds and administered to patients.

[0037] As a specific embodiment of the combined use of two or more drug ingredients, the drug is a pharmaceutical composition, which contains a therapeutically effective amount of NAD+, and / or a P2Y12 receptor antagonist, and / or other antiplatelet drug ingredients.

[0038] It should be understood that the term "or" as used herein sometimes means "and / or" and the term "or" sometimes means "and / or". The term "and / or" as used in phrases such as "A and / or B" herein is intended to include both A and B; A or B; A (alone); and B (alone). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to cover each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0039] The phrase "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, and are commensurate with a reasonable benefit / risk ratio, within the scope of reasonable medical judgment. Pharmaceutically acceptable carriers are well known in the art, and these carriers include liquid or solid fillers, diluents, excipients, solvents or encapsulating materials. Each carrier must be "acceptable" in the sense that it is compatible with the other ingredients of the formulation and harmless to the patient, including, for example, aqueous solutions (such as water or physiological buffered saline) or other solvents or vehicles (such as glycols, glycerol, oils (such as olive oil) or injectable organic esters). Excipients can be selected, for example, to achieve delayed release of the medicament or to selectively target one or more cells, tissues or organs. The pharmaceutical composition can be in the form of dosage units, such as tablets, capsules (including dispersed capsules and gelatin capsules), granules, powders, solutions, syrups, suppositories, injections, etc.

[0040] As used herein, the term "effective amount" refers to the amount of treatment required to alleviate at least one or more symptoms of a disease or condition, and relates to a sufficient amount of a drug to provide the desired effect. Therefore, the term "therapeutically effective amount" refers to a therapeutic amount sufficient to cause a specific effect when administered to a typical subject. In various contexts, an effective amount as used herein also includes an amount sufficient to delay the development of a disease condition, change the course of a disease condition (for example, but not limited to, slowing the progression of a disease condition), or reverse a disease condition. It should be understood that there are many ways known in the art to determine the effective amount for a given application. For example, pharmacological methods for dosage determination can be used in the treatment context. In the context of therapeutic or preventive applications, the amount of the composition administered to the subject will depend on the type and severity of the disease and the characteristics of the individual, such as overall health, age, sex, weight, and tolerance to drugs. It also depends on the extent, severity, and type of the disease. Those skilled in the art will be able to determine the appropriate dose based on these and other factors. For example, the therapeutically effective amount of NAD+ can be determined by reference to its current safe use amount for the treatment of arterial thrombotic disease in patients with arterial thrombotic disease, and by clinical investigation. The appropriate effective dosage also needs to take into account therapeutic factors such as the dosage form of the drug, the constitution, weight, age, disease progression, and administration site of the individual being administered.

[0041] As previously mentioned, the pharmaceutical ingredient NAD+ can also be administered in combination with one or more additional therapeutic compounds such as a P2Y12 receptor antagonist.

[0042] In addition to the main component NAD+, the pharmaceutical dosage form may also contain a pharmaceutically acceptable carrier. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars (such as lactose, glucose, and sucrose); (2) starches (such as corn starch and potato starch); (3) cellulose and its derivatives (such as sodium carboxymethylcellulose, ethyl cellulose, and cellulose acetate); (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients (such as cocoa butter and suppository wax); (9) oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn starch, etc.) oil and soybean oil); (10) glycols (such as propylene glycol); (11) polyols (such as glycerol, sorbitol, mannitol and polyethylene glycol); (12) esters (such as ethyl oleate and ethyl laurate); (13) agar; (14) buffers (such as magnesium hydroxide and aluminum hydroxide); (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other non-toxic compatible substances used in pharmaceutical preparations.

[0043] The pharmaceutical preparation can be administered to a subject by any of a number of routes of administration, including, for example, oral (e.g., as a drench, tablet, capsule (including dispersible capsules and gelatin capsules) in an aqueous or non-aqueous solution or suspension, bolus, powder, granules, paste for application to the tongue); absorption through the oral mucosa (e.g., sublingually); subcutaneously; transdermally (e.g., as a patch applied to the skin); and topically (e.g., as a cream, ointment, or spray applied to the skin). NAD+ can also be formulated for inhalation. In certain embodiments, NAD+ can simply be dissolved or suspended in a sterile solvent.

[0044] The above-mentioned term "subject" means a person or an animal. Generally, an animal is a vertebrate, such as a primate, a rodent, a domestic animal or a game animal. Primates include chimpanzees, crab-eating monkeys, spider monkeys and macaques, such as rhesus monkeys. Rodents include mice, rats, marmots, ferrets, rabbits and hamsters. Domestic animals and game animals include cattle, horses, pigs, deer, bison, buffaloes, feline species (such as house cats), canine species (such as dogs, foxes, wolves). In some embodiments, the subject is a mammal, such as a primate such as a human. The terms "individual", "patient" and "subject" are used interchangeably herein. Preferably, the subject is a mammal. The mammal can be a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse or a cow, but is not limited to these examples. The subject can be male or female.

[0045] The pharmaceutical preparation can be conveniently presented in unit dosage form and can be prepared by any method well known in the pharmaceutical field. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will vary according to the host being treated, the specific mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be the amount of the compound that produces the therapeutic effect. Typically, by weight, this amount ranges from about 1% to about 99% active ingredient, for example, from about 5% to about 70%.

[0046] Methods for preparing these formulations or compositions include the step of combining the active compound (such as NAD+) with a carrier and optionally one or more auxiliary ingredients. In general, the formulation is prepared by uniformly and intimately combining NAD+ with a liquid carrier or a finely divided solid carrier or both, and then shaping the product if necessary.

[0047] Formulations of the invention suitable for oral administration may be in the form of capsules (including dispersible capsules and gelatin capsules), cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), lyophiles, powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a pastille (using an inert base such as gelatin and glycerin, or sucrose and acacia) and / or as a mouthwash, etc., each containing a predetermined amount of NAD+ as the active ingredient. The composition or compound may also be administered as a bolus, electuary, or paste.

[0048] To prepare solid dosage forms for oral administration (capsules (including dispersible capsules and gelatin capsules), tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with one or more pharmaceutically acceptable carriers (such as sodium citrate or dicalcium phosphate) and / or any of the following: (1) fillers or extenders (such as starch, lactose, sucrose, glucose, mannitol and / or silicic acid); (2) binders (such as, for example, carboxymethylcellulose, alginate, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia); (3) wetting agents (such as glycerol); (4) disintegrants (such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate); (5) solution retardants (such as paraffin); (6) absorption accelerators (such as quaternary ammonium compounds); (7) wetting agents (such as, for example, cetyl alcohol and glyceryl monostearate); (8) absorbents (such as kaolin and bentonite); (9) lubricants (such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium laurate sulfate, and mixtures thereof); (10) complexing agents (such as modified or unmodified cyclodextrins); and (11) coloring agents. In the case of capsules (including dispersible capsules and gelatin capsules), tablets, and pills, the pharmaceutical composition may also contain a buffer. Solid compositions of a similar type may also be used as fillers in soft-filled and hard-filled gelatin capsules using such excipients as lactose and high molecular weight polyethylene glycols and the like.

[0049] Tablets can be made by compression or molding, optionally using one or more auxiliary ingredients. Compressed tablets can be prepared using a binder (e.g., gelatin or hydroxypropyl methylcellulose), a lubricant, an inert diluent, a preservative, a disintegrant (e.g., sodium starch glycolate, or cross-linked sodium carboxymethyl cellulose), a surfactant or a dispersant. Molded tablets can be made by molding a mixture of a powdered compound moistened with an inert liquid diluent in a suitable machine.

[0050] Tablets and other solid dosage forms of pharmaceutical compositions (such as dragees, capsules (including dispersible capsules and gelatin capsules), pills and granules) may optionally be scored, or prepared with coatings and shells (such as enteric coatings and other coatings well known in the art of pharmaceutical formulation). They may also be formulated to provide slow release or controlled release of the active ingredient therein, using, for example, hydroxypropylmethylcellulose in different proportions to provide the desired release curve, other polymer matrices, liposomes and / or microspheres. They may be sterilized by, for example, filtering through a filter that retains bacteria, or by incorporating a sterilizing agent in the form of a sterile solid composition, which may be dissolved in sterile water or some other sterile injectable medium just before use. These compositions may also optionally contain an emulsifier, and may be a composition that releases one or more active ingredients only or preferentially in a certain part of the gastrointestinal tract (optionally, in a delayed manner). Examples of embedding compositions that may be used include polymeric substances and waxes. The active ingredient may also be in microencapsulated form, with one or more of the above-mentioned excipients when appropriate.

[0051] Liquid dosage forms useful for oral administration include pharmaceutically acceptable emulsions, lyophiles for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art (such as, for example, water or other solvents, cyclodextrins and derivatives thereof), solubilizers and emulsifiers (such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, groundnut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuran alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof).

[0052] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0053] Suspensions, in addition to the active compounds, may contain suspending agents (such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof).

[0054] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers or propellants that may be required.

[0055] Ointments, pastes, creams and gels may contain, in addition to the active compounds, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0056] In addition to the active compound, powders and sprays may contain excipients (such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder, or mixtures of these substances). Sprays may additionally contain customary propellants (such as chlorofluorocarbons and volatile unsubstituted hydrocarbons (such as butane and propane)).

[0057] Transdermal patches have the additional advantage of providing controlled delivery of the active compound to the body. Such dosage forms can be manufactured by dissolving or dispersing the active compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. The rate of such flux can be controlled by providing a rate-controlled membrane or by dispersing the compound in a polymer matrix or a gel.

[0058] The example of suitable aqueous carrier and non-aqueous carrier that can be used in the pharmaceutical composition of the present invention includes water, ethanol, polyol (such as glycerol, propylene glycol, polyethylene glycol, etc.) and its suitable mixture, vegetable oil (such as olive oil) and injectable organic ester (such as ethyl oleate). The example of suitable aqueous carrier and non-aqueous carrier that can be used in the pharmaceutical composition of the present invention includes water, ethanol, polyol (such as glycerol, propylene glycol, polyethylene glycol, etc.) and its suitable mixture, vegetable oil (such as olive oil) and injectable organic ester (such as ethyl oleate). For example, by using coating material (such as lecithin), by keeping required particle size in the case of dispersion, and by using surfactant, keep suitable fluidity. For example, by using coating material (such as lecithin), by keeping required particle size in the case of dispersion, and by using surfactant, keep suitable fluidity.

[0059] These compositions can also contain adjuvants (such as preservatives, wetting agents, emulsifiers and dispersants). It is possible to ensure the prevention of microbial effects by including various antibacterial and antifungal agents (for example, methylparaben, chlorobutanol, phenol sorbic acid, etc.). It is also desirable to include isotonic agents (such as sugar, sodium chloride, etc.) in the composition. In addition, extended absorption of injectable drug forms can be caused by including agents that delay absorption (such as aluminum monostearate and gelatin).

[0060] In some cases, in order to prolong the effect of the drug, it is desirable to slow down the absorption of the drug from subcutaneous injection or intramuscular injection. This can be achieved by using a liquid suspension of a crystalline material or amorphous material with poor water solubility. The absorption rate of the drug depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, the delayed absorption of the drug form administered parenterally is achieved by dissolving or suspending the drug in an oil vehicle.

[0061] Injectable reservoir forms are made by forming a microencapsulated matrix of the subject compound in a biodegradable polymer (such as polylactide-polyglycolide). Depending on the ratio of the drug to the polymer and the properties of the specific polymer employed, the drug release rate can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Reservoir injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions compatible with body tissues.

[0062] For use in the methods of the invention, the active compound may be administered per se or as a pharmaceutical composition containing, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of the active ingredient in combination with a pharmaceutically acceptable carrier.

[0063] Actual dosage levels of the active ingredients in the pharmaceutical compositions may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0064] The selected dosage level will depend upon a variety of factors including the activity of the specific compound or combination of compounds employed, or the esters, salts or amides thereof, the route of administration, the time of administration, the rate of excretion of the specific compound or compounds employed, the duration of the treatment, other drugs, compounds and / or materials used in combination with the specific compound or compounds employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0065] A physician or veterinarian with ordinary skills in the art can easily determine and prescribe the therapeutically effective amount of the required pharmaceutical composition. For example, the physician or veterinarian can start with a dose of the pharmaceutical composition or compound that is below the level required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. "Therapeutically effective amount" means the concentration of the compound sufficient to cause the desired therapeutic effect. It is generally understood that the effective amount of the compound will vary according to the weight, sex, age and medical history of the subject. Other factors affecting the effective amount may include, but are not limited to, the severity of the patient's condition, the condition being treated, the stability of the compound, and (if necessary) another type of therapeutic agent administered with NAD+. A larger total dose can be delivered by multiple administrations of the agent. Methods for determining efficacy and dosage are known to those skilled in the art.

[0066] In general, a suitable daily dose of the active compound used in the compositions and methods of the invention will be the amount of the compound that is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend on the factors described above.

[0067] If desired, the effective daily dose of the active compound may be administered as one, two, three, four, five, six or more sub-doses, optionally in unit dosage form, at appropriate intervals throughout the day. In certain embodiments of the invention, the active compound may be administered twice or three times a day. In other embodiments, the active compound will be administered once a day.

[0068] Patients receiving such treatment are any animal in need thereof, including primates (particularly humans); and other mammals (such as horses, cattle, pigs, sheep, cats, and dogs); poultry; and pets in general.

[0069] The present invention is further described in detail below in conjunction with specific examples. It should be understood that the following examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0070] In the embodiments of the present invention, if there is no specific description on the experimental operation temperature, the temperature generally refers to room temperature (15-35° C.).

[0071] This article involves the addition amount, content and concentration of various substances, and the percentages mentioned here refer to the mass percentages unless otherwise specified.

[0072] Statistical analysis: In this study, all numerical variables were expressed as mean ± standard error. The two-group comparison was performed using the two-tailed Student t test, and the three-group comparison was performed using the ANOVA test. When P < 0.05, it was considered to be statistically significant.

[0073] The experimental methods in the following examples without specifying specific conditions are generally carried out according to the conditions recommended by the manufacturer or the conditions described in Platelets, Second Edition (New York: Elsevier Press, 2007). Unless otherwise specified, the reagents used in the text are from Sinopharm Reagent Co., Ltd.

[0074] Example 1: Inhibitory effect of NAD+ on collagen-induced human platelet aggregation

[0075] Preparation of platelets: Human platelets were collected from healthy volunteers who voluntarily signed informed consent forms at Zhongshan Hospital affiliated to Fudan University. The volunteers had not taken any antiplatelet drugs such as aspirin and clopidogrel before blood collection. Blood was drawn from the median cubital vein and collected in a centrifuge tube containing ACD anticoagulant (ACD anticoagulant formula: 85mmol / L sodium citrate, 71.38mmol / L citric acid, 27.78mmol / L glucose). The collected whole blood was gently mixed and centrifuged at 300g×20min. The whole blood was divided into two layers, and the upper layer was platelet-rich plasma. The platelet-rich plasma was centrifuged again at 900g×10min. The platelet precipitate at the bottom was washed with a benchtop solution containing 0.02u / mL apyrase (benchtop solution formula: 138mmol / L sodium chloride, 2.7mmol / L potassium chloride, 2mmol / L magnesium chloride, 0.42mmol / L sodium dihydrogen phosphate, 5mmol / L glucose, 10mmol / L HEPES, 0.2% bovine serum albumin, 0.02mmol / L adenylate hydrolase, pH 7.4), and 40 μl was counted. According to the counting results, the platelet concentration was adjusted to 2.5×10 8 Pieces / mL.

[0076] Determination of platelet aggregation and release: The washed platelets obtained by gradient centrifugation were placed in a 37°C incubator for 20-30 minutes to allow them to rest. The platelet aggregation instrument (Model 400VS, Chrono-Log, Haverston, PA) was turned on in advance and its temperature was raised to 37°C to simulate the human body environment. The paper feed speed was set to 1 cm / min, and a solvent desktop liquid was added to the control tube. The aggregation rate of the control group was 100%. 0.75 μL of NAD+ with concentrations of 0mM, 10mM, 15mM, 20mM, 25mM, and 30mM was taken and added to 300 μL of platelets. The platelets were incubated at 37°C for 30 minutes. 0 μM was equivalent to adding only saline. The final concentrations of the drug were 0 μM, 50 μM, 75 μM, 100 μM, 125 μM, and 150 μM. The agonist collagen was added and the aggregation curve was observed and recorded. Finally, the results were recorded and the data were statistically analyzed. Figure 1 shown.

[0077] Figure 1 Figures A and B show that compared with the control group, NAD+ concentration-dependently inhibited the agonist collagen-induced human platelet aggregation, and the difference was statistically significant.

[0078] The results of this example demonstrate that NAD+ can inhibit the aggregation of human platelets induced by the agonist collagen.

[0079] Example 2: Inhibitory effect of NAD+ on arterial thrombosis in mice

[0080] Each mouse was intraperitoneally injected with NAD+ (10 mg / kg) 1 hour before the experiment. The mice were anesthetized with pentobarbital, and blood was collected from the abdominal aorta. Platelet precipitation was obtained by gradient centrifugation. TB was then resuspended to obtain WP, and the WP concentration was adjusted to 500×10 10 / L, add the fluorescent dye calcein (2.67μg / mL) to it, put it in a 37-degree incubator, incubate it away from light for 20 minutes, and wait until it turns yellow-green. Anesthetize the mouse, wait for it to lose consciousness, fix it on the operating table, remove the hair on the thigh surface, cut the thigh skin to expose the femoral vein, and inject 100 μL of 500×10 10 / L of fluorescent platelets were slowly infused back into the mouse through the femoral vein. After the fluorescent platelets were successfully infused back into the mouse, the mouse's abdominal hair was removed, the abdominal cavity was opened along the midline of the abdomen, and a small amount of small intestine was squeezed out by pressing on both sides of the mouse's abdomen. A new culture dish was taken, and a slide was placed in the center of the culture dish. The slide was moistened with saline, and the mouse was placed in the dish on one side of the slide. The small intestine was placed on the slide, and the small intestine was gently opened with a cotton swab soaked in saline. The small intestine was spread on the slide to expose the mesenteric artery. The mesenteric artery was observed under a microscope, placed in the center of the lens, and stained with 10% FeCl 3 The blood vessels were damaged by moistened filter paper for 2 minutes, the filter paper was removed, the thrombus formation was observed, the video was saved, and the time of the first stable thrombus formation larger than 20 μm and the time of blood flow interruption were recorded. A thrombus that was not washed away for more than 2 minutes was considered a stable thrombus, and blood flow cessation lasting for 2 minutes was considered a blood flow interruption. The data were saved and statistically analyzed. Figure 2 shown.

[0081] Figure 2 It was shown that NAD+ (10 mg / kg) significantly inhibited arterial thrombosis in mice compared with the control group.

[0082] The results of this example demonstrate that NAD+ can inhibit arterial thrombosis in mice.

[0083] Example 2: Effect of NAD+ on bleeding in mice

[0084] Each mouse was intraperitoneally injected with NAD+ (10 mg / kg) 1 hour before the experiment. The mice were anesthetized with pentobarbital. After the mice were fully anesthetized, the end of the tail was cut off by 0.5 cm. The tail was placed in 37°C preheated saline and the time from the beginning of bleeding to the cessation of bleeding was observed. Figure 3 shown.

[0085] Figure 3 The results showed that compared with the control group, NAD+ did not affect the tail bleeding time of mice, and the difference was not statistically significant (P>0.05).

[0086] The results of this example demonstrate that NAD+ does not affect bleeding in mice.

[0087] The above examples illustrate the technical solution of the present invention, confirming that NAD+ has a strong inhibitory effect on agonist-induced platelet aggregation; FeCl 3 The results of the injury-induced mesenteric artery thrombosis experiment showed that NAD+ also has a strong inhibitory effect on thrombosis, and the results of the tail bleeding experiment showed that NAD+ did not increase the risk of mice, suggesting that NAD+ provides a new option for the prevention and treatment of arterial thrombotic diseases.

[0088] It should be understood that the above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of nicotinamide adenine dinucleotide in the preparation of antiplatelet drugs.

2. The use according to claim 1, characterized in that The antiplatelet agent refers to the inhibition of platelet aggregation and thrombosis.

3. The use according to claim 1, characterized in that The antiplatelet drug is a thrombus prevention or antithrombotic drug.

4. The use according to claim 1, characterized in that The antiplatelet drug is a drug for preventing or treating arterial thrombotic diseases.

5. The use according to claim 4, characterized in that The arterial thrombotic disease is coronary heart disease, myocardial infarction or cerebral stroke.

6. An antiplatelet drug, characterized in that: The drug contains a therapeutically effective amount of nicotinamide adenine dinucleotide as the only active ingredient, or the drug is a pharmaceutical composition, which, in addition to containing a therapeutically effective amount of nicotinamide adenine dinucleotide as an active ingredient, also contains other antiplatelet drug ingredients.

7. The antiplatelet drug according to claim 6, characterized in that The dosage form of the drug is an oral preparation or an injection.

8. The antiplatelet drug according to claim 7, characterized in that: The oral preparation is selected from the group consisting of tablets, capsules, granules, powders, solutions, and syrups; the injection is suitable for intravenous injection or intravenous drip.

Citation Information

Patent Citations

  • Application of nicotinamide adenine dinucleotide in preparation of drug for preventing and treating heart ischemic injuries

    CN105168236A

  • Medicine for treating ischemic cerebral stroke as well as preparation method and application of medicine

    CN106511366A

  • Composition for improving NAD+ level and application thereof

    CN113712987A

  • Method and system for treating person suffering from a circulatory disorder

    US20150290073A1

  • Composition for microbiota transplantation, method for preparing same, and use thereof in preparing medicament for improving NAD+ level

    WO2024125659A1